Vadecum pediatrico

Medicamentos en pediatría
The Harriet Lane Handbook. 17 ed. 2005
Part IV – Formulary

Contents:
o o o o o o o o o o o o o o o o o o o o o o o o o o o

I.. NOTE TO THE READER 2 II.. SAMPLE ENTRY 3 III.. EXPLANATION OF BREAST-FEEDING CATEGORIES 4 IV.. EXPLANATION OF PREGNANCY CATEGORIES 4 VI.. DRUG DOSES: A 5 VI.. DRUG DOSES: B 46 VI.. DRUG DOSES: C 60 VI.. DRUG DOSES: D 116 VI.. DRUG DOSES:E 144 VI.. DRUG DOSES: F 161 VI.. DRUG DOSES: G183 VI.. DRUG DOSES: H192 VI.. DRUG DOSES: I 202 VI.. DRUG DOSES: K218 VI.. DRUG DOSES: L 222 VI.. DRUG DOSES: M241 VI.. DRUG DOSES: N 273 VI.. DRUG DOSES: O 290 VI.. DRUG DOSES: P 304 VI.. DRUG DOSES: Q357 VI.. DRUG DOSES: R359 VI.. DRUG DOSES: S 371 VI.. DRUG DOSES: T 392 VI.. DRUG DOSES: U412 VI.. DRUG DOSES: V414 VI.. DRUG DOSES: W429 VI.. DRUGDOSES: Z431

1

Drug Doses Carlton Lee, PharmD, MPH Jason Robertson, MD Nicole Shilkofski, MD I. NOTE TO THE READER The authors have made every attempt to check dosages and medical content for accuracy. Because of the incomplete data on pediatric dosing, many drug dosages will be modified after the publication of this text. We recommend that the reader check product information and publishedliterature for changes in dosing, especially for newer medicines.

2

II. SAMPLE ENTRY

3

III. EXPLANATION OF BREAST-FEEDING CATEGORIES See sample entry. 1 Compatible 2 Use with caution 3 Unknown with concerns X Contraindicated ? Safety not established IV. EXPLANATION OF PREGNANCY CATEGORIES A Adequate studies in pregnant women have not demonstrated a risk to the fetus in the firsttrimester of pregnancy, and there is no evidence of risk in later trimesters. B Animal studies have not demonstrated a risk to the fetus, but there are no adequate studies in pregnant women; or animal studies have shown an adverse effect, but adequate studies in pregnant women have not demonstrated a risk to the fetus during the first trimester of pregnancy, and there is no evidence of risk in latertrimesters. C Animal studies have shown an adverse effect on the fetus, but there are no adequate studies in humans; or there are no animal reproduction studies and no adequate studies in humans. D There is evidence of human fetal risk, but the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks. X Studies in animals or humans demonstrate fetalabnormalities or adverse reaction; reports indicate evidence of fetal risk. The risk of use in pregnant woman clearly outweighs any possible benefit.

4

VI. DRUG DOSES: A ACETAMINOPHEN ACETAMINOPHEN Tylenol, Tempra, Panadol, Feverall, Anacin-3, and others Yes 1 Analgesic, antipyretic Tabs: 160, 325, 500, 650 mg Chewable tabs: 80, 160 mg Infant drops, solution/suspension: 80 mg/0.8 mL Childsuspension/syrup: 160 mg/5 mL Oral liquid: 160, 166.7 mg/5 mL Elixir: 160 mg/5 mL Caplet: 500 mg Extended-release caplet/geltab: 650 mg Gelcap: 500 mg Capsules: 500, 650 mg Suppositories: 80, 120, 325, 650 mg

B

(Combination product with Codeine, see Codeine and Acetaminophen) Neonates: 10–15 mg/kg/dose PO/PR Q6–8 hr. Some advocate loading doses of 20–25 mg/kg/dose for PO dosing or 30mg/kg/dose for PR dosing. Pediatric: 10–15 mg/kg/dose PO/PR Q4–6 hr. For rectal dosing, some may advocate a 40–45 mg/kg/dose loading dose. Dosing by age (PO/PR Q4–6 hr): 0–3 mo: 40 mg/dose
5

4–11 mo: 80 mg/dose 12–24 mo: 120 mg/dose 2–3 yr: 160 mg/dose 4–5 yr: 240 mg/dose 6–8 yr: 320 mg/dose 9–10 yr: 400 mg/dose 11–12 yr: 480 mg/dose Adult: 325–650 mg/dose Max. dose: 4 g/24 hr, 5 doses/24 hr Doesnot possess anti-inflammatory activity. Use with caution in patients with known G6PD deficiency. T1/2: 1–3 hr, 2–5 hr in neonates; metabolized in the liver; see Chapter 2 , Table 2–3 for management of overdosage. Some preparations contain alcohol (7%–10%) and/or phenylalanine; all suspensions should be shaken before use. May decrease the activity of lamotrigine and increase the activity of...